Testing effectiveness (Phase 2)Looking for participantsNCT05438420
What this trial is testing
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Who this might be right for
Esophageal CancerGastric CancerHepatocellular Cancer+1 more
Qurient Co., Ltd. 120